Samsung Biologics wins $1.24 bil. deal for contract manufacturing

Samsung Biologics' plant 4 in Songdo, Incheon / Courtesy of Samsung Biologics Samsung Biologics said Tuesday it has signed a deal worth $1.24 billion for contract manufacturing from an Asia-based biopharmaceutical firm. The deal will last until the end of 2037, the company said in a regulatory filing.

Other details remained undisclosed under a confidentiality agreement. Samsung Biologics said the deal reaches almost half of the value of its combined manufacturing deals for last year at 3.5 trillion won ($2.



53 billion). So far this year, Samsung Biologics has secured nine deals worth a combined 4.36 trillion won with global biopharmaceutical companies.

(Yonhap).